drugset
drugset / Trial / NCT05970016

A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.

NCT05970016 ↗

Phase 1/2 Recruiting 56 enrolled Beijing Tide Pharmaceutical Co., Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.

Timeline

Start
2023-08-07
Primary completion
2025-07-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TCC1727 Unknown 5 mg Oral
Subject TCC1727 Unknown 10 mg Oral
Subject TCC1727 Unknown 20 mg Oral
Subject TCC1727 Unknown 40 mg Oral
Subject TCC1727 Unknown 60 mg Oral
Subject TCC1727 Unknown 80 mg Oral
Subject TCC1727 Unknown 90 mg Oral
Subject TCC1727 Unknown 100 mg Oral
Subject TCC1727 Unknown 120 mg Oral
Subject TCC1727 Unknown 160 mg Oral

Indications

No indication recorded.